|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Lepisto AJ, Moser AJ, Zeh H, et al: A
phase I/II study of a MUC1 peptide pulsed autologous dendritic cell
vaccine as adjuvant therapy in patients with resected pancreatic
and biliary tumors. Cancer Ther. 6:955–964. 2008.PubMed/NCBI
|
|
3
|
Gjertsen MK, Bakka A, Breivik J, et al:
Vaccination with mutant ras peptides and induction of T-cell
responsiveness in pancreatic carcinoma patients carrying the
corresponding RAS mutation. Lancet. 346:1399–1400. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Laheru D and Jaffee EM: Immunotherapy for
pancreatic cancer - science driving clinical progress. Nat Rev
Cancer. 5:459–467. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Argani P, Iacobuzio-Donahue C, Ryu B, et
al: Mesothelin is overexpressed in the vast majority of ductal
adenocarcinomas of the pancreas: identification of a new pancreatic
cancer marker by serial analysis of gene expression (SAGE). Clin
Cancer Res. 7:3862–3868. 2001.PubMed/NCBI
|
|
6
|
Liyanage UK, Moore TT, Joo HG, et al:
Prevalence of regulatory T cells is increased in peripheral blood
and tumor microenvironment of patients with pancreas or breast
adenocarcinoma. J Immunol. 169:2756–2761. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Soares KC, Zheng L, Edil B and Jaffee EM:
Vaccines for pancreatic cancer. Cancer J. 18:642–652. 2012.
View Article : Google Scholar
|
|
8
|
Galili U, Clark MR, Shohet SB, Buehler J
and Macher BA: Evolutionary relationship between the natural
anti-Gal antibody and the Gal alpha 1→3Gal epitope in primates.
Proc Natl Acad Sci USA. 84:1369–1373. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tanemura M, Yin D, Chong AS and Galili U:
Differential immune responses to alpha-gal epitopes on xenografts
and allografts: implications for accommodation in
xenotransplantation. J Clin Invest. 105:301–310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tanemura M, Saga A, Kawamoto K, et al: In
vitro and in vivo prevention of human CD8+ CTL-mediated
xenocytotoxicity by pig c-FLIP expression in porcine endothelial
cells. Am J Transplant. 8:288–297. 2008. View Article : Google Scholar
|
|
11
|
Galili U and LaTemple DC: Natural anti-Gal
antibody as a universal augmenter of autologous tumor vaccine
immunogenicity. Immunol Today. 18:281–285. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Deguchi T, Tanemura M, Miyoshi E, et al:
Increased immunogenicity of tumor-associated antigen, mucin 1,
engineered to express alpha-gal epitopes: a novel approach to
immunotherapy in pancreatic cancer. Cancer Res. 70:5259–5269. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Z, Li Y, Ahmad A, et al: Pancreatic
cancer: understanding and overcoming chemoresistance. Nat Rev
Gastroenterol Hepatol. 8:27–33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li C, Heidt DG, Dalerba P, et al:
Identification of pancreatic cancer stem cells. Cancer Res.
67:1030–1037. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
LaTemple DC and Galili U: Adult and
neonatal anti-Gal response in knock-out mice for
alpha1,3-galactosyltransferase. Xenotransplantation. 5:191–196.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thall AD, Maly P and Lowe JB: Oocyte Gal
alpha 1,3Gal epitopes implicated in sperm adhesion to the zona
pellucida glycoprotein ZP3 are not required for fertilization in
the mouse. J Biol Chem. 270:21437–21440. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sipos B, Moser S, Kalthoff H, Torok V,
Lohr M and Kloppel G: A comprehensive characterization of
pancreatic ductal carcinoma cell lines: towards the establishment
of an in vitro research platform. Virchows Arch. 442:444–452.
2003.PubMed/NCBI
|
|
18
|
LaTemple DC, Henion TR, Anaraki F and
Galili U: Synthesis of alpha-galactosyl epitopes by recombinant
alpha1,3galactosyl transferase for opsonization of human tumor cell
vaccines by anti-galactose. Cancer Res. 56:3069–3074.
1996.PubMed/NCBI
|
|
19
|
Tanemura M, Maruyama S and Galili U:
Differential expression of alpha-GAL epitopes
(Galalpha1–3Galbeta1–4GlcNAc-R) on pig and mouse organs.
Transplantation. 69:187–190. 2000. View Article : Google Scholar
|
|
20
|
Kawamoto K, Tanemura M, Nishida T,
Fukuzawa M, Ito T and Matsuda H: Significant inhibition of human
CD8(+) cytotoxic T lymphocyte-mediated xenocytotoxicity by
overexpression of the human decoy Fas antigen. Transplantation.
81:789–796. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
LaTemple DC, Abrams JT, Zhang SY and
Galili U: Increased immunogenicity of tumor vaccines complexed with
anti-Gal: studies in knockout mice for
alpha1,3-galactosyltransferase. Cancer Res. 59:3417–3423.
1999.PubMed/NCBI
|
|
22
|
Thomas AM, Santarsiero LM, Lutz ER, et al:
Mesothelin-specific CD8+ T cell responses provide
evidence of in vivo cross-priming by antigen-presenting cells in
vaccinated pancreatic cancer patients. J Exp Med. 200:297–306.
2004. View Article : Google Scholar
|
|
23
|
Jaffee EM, Hruban RH, Biedrzycki B, et al:
Novel allogeneic granulocyte-macrophage colony-stimulating
factor-secreting tumor vaccine for pancreatic cancer: a phase I
trial of safety and immune activation. J Clin Oncol. 19:145–156.
2001.
|
|
24
|
Hassan R and Ho M: Mesothelin targeted
cancer immunotherapy. Eur J Cancer. 44:46–53. 2008. View Article : Google Scholar
|
|
25
|
Galili U, Chen ZC and DeGeest K:
Expression of alpha-gal epitopes on ovarian carcinoma membranes to
be used as a novel autologous tumor vaccine. Gynecol Oncol.
90:100–108. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ladjemi MZ, Jacot W, Chardes T, Pelegrin A
and Navarro-Teulon I: Anti-HER2 vaccines: new prospects for breast
cancer therapy. Cancer Immunol Immunother. 59:1295–1312. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tang CK, Katsara M and Apostolopoulos V:
Strategies used for MUC1 immunotherapy: human clinical studies.
Expert Rev Vaccines. 7:963–975. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu JP, Chen W, Schwarer AP and Li H:
Telomerase in cancer immunotherapy. Biochim Biophys Acta.
1805:35–42. 2010.PubMed/NCBI
|
|
29
|
Ryan BM, O’Donovan N and Duffy MJ:
Survivin: a new target for anti-cancer therapy. Cancer Treat Rev.
35:553–562. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saito H, Dubsky P, Dantin C, Finn OJ,
Banchereau J and Palucka AK: Cross-priming of cyclin B1, MUC-1 and
survivin-specific CD8+ T cells by dendritic cells loaded
with killed allogeneic breast cancer cells. Breast Cancer Res.
8:R652006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schnurr M, Scholz C, Rothenfusser S, et
al: Apoptotic pancreatic tumor cells are superior to cell lysates
in promoting cross-priming of cytotoxic T cells and activate NK and
gammadelta T cells. Cancer Res. 62:2347–2352. 2002.PubMed/NCBI
|
|
32
|
Bohnenkamp HR, Coleman J, Burchell JM,
Taylor-Papadimitriou J and Noll T: Breast carcinoma cell
lysate-pulsed dendritic cells cross-prime MUC1-specific
CD8+ T cells identified by peptide-MHC-class-I
tetramers. Cell Immunol. 231:112–125. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Palucka AK, Ueno H, Connolly J, et al:
Dendritic cells loaded with killed allogeneic melanoma cells can
induce objective clinical responses and MART-1 specific
CD8+ T-cell immunity. J Immunother. 29:545–557. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fields RC, Shimizu K and Mule JJ: Murine
dendritic cells pulsed with whole tumor lysates mediate potent
antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci
USA. 95:9482–9487. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Brossart P and Bevan MJ: Presentation of
exogenous protein antigens on major histocompatibility complex
class I molecules by dendritic cells: pathway of presentation and
regulation by cytokines. Blood. 90:1594–1599. 1997.PubMed/NCBI
|
|
36
|
Shen Z, Reznikoff G, Dranoff G and Rock
KL: Cloned dendritic cells can present exogenous antigens on both
MHC class I and class II molecules. J Immunol. 158:2723–2730.
1997.PubMed/NCBI
|
|
37
|
Shakhar G and Ben-Eliyahu S: Potential
prophylactic measures against postoperative immunosuppression:
could they reduce recurrence rates in oncological patients? Ann
Surg Oncol. 10:972–992. 2003. View Article : Google Scholar
|
|
38
|
Weighardt H, Heidecke CD, Emmanuilidis K,
et al: Sepsis after major visceral surgery is associated with
sustained and interferon-gamma-resistant defects of monocyte
cytokine production. Surgery. 127:309–315. 2000. View Article : Google Scholar
|
|
39
|
Livingston P: The unfulfilled promise of
melanoma vaccines. Clin Cancer Res. 7:1837–1838. 2001.PubMed/NCBI
|
|
40
|
Khong HT and Restifo NP: Natural selection
of tumor variants in the generation of ‘tumor escape’ phenotypes.
Nat Immunol. 3:999–1005. 2002. View Article : Google Scholar
|
|
41
|
Dunn GP, Bruce AT, Ikeda H, Old LJ and
Schreiber RD: Cancer immunoediting: from immunosurveillance to
tumor escape. Nat Immunol. 3:991–998. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Campbell PJ, Yachida S, Mudie LJ, et al:
The patterns and dynamics of genomic instability in metastatic
pancreatic cancer. Nature. 467:1109–1113. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yachida S, Jones S, Bozic I, et al:
Distant metastasis occurs late during the genetic evolution of
pancreatic cancer. Nature. 467:1114–1117. 2010. View Article : Google Scholar : PubMed/NCBI
|
